CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 336 enrolled
Drug / intervention
U0267 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00688519
NCT00688519Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267, Versus Vehicle in Subjects With Plaque-type Psoriasis

Stiefel, a GSK Company·interventional·Posted Jun 3, 2008·Updated Jan 2, 2017

In Brief

A Phase 3 clinical trial evaluating U0267 and Vehicle for Psoriasis. Completed, enrolled 336 participants across 13 sites.

Detailed Summary

The purpose of the study is to demonstrate the safety and efficacy of U0267 in subjects with plaque-type psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 3, 2008
Enrollment StartMar 1, 2008
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.1 years ago

Interventions

U0267drug

All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).

Vehicledrug

All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).